|
|
Article: Genentech, Amgen settle patent dispute over lucrative drug
- Article from:
- AP Worldstream
- Article date:
- August 28, 2003
CopyrightProvided by ProQuest LLC. (Hide copyright information)
|
00-00-0000
Dateline: SAN FRANCISCO
Biotechnology rivals Genentech Inc. and Amgen Inc. have settled a
long-running patent dispute over the technology used to produce one
of Amgen's top-selling products.
Genentech sued seven years ago in U.S. District Court alleging that
Amgen had infringed on three of its patents while developing Neupogen,
a drug used to fight infections in cancer patients undergoing chemotherapy.
Last year, Neupogen sales brought Amgen $1.3 billion.
Under terms of the settlement announced Wednesday, Amgen agreed to
make a one-time payment to Genentech, but the company said it would
not license any of Genentech's patents. Financial terms were not disclosed.
As ...